The safety and tolerability profile of the drug over the nearly 200-week trial was consistent with previous results of the 72-week benchmark in SURMOUNT-1
Retrieved 10 October 2021, from King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H
Common early side effects include nausea, reduced appetite, occasional vomiting, and changes in bowel habits
N-acetylcysteine (NAC) may benefit patients with severe oxidative damage (e.g., diabetic nephropathy) by replenishing glutathione ( Given the variability in individual redox status, future strategies should consider measuring OS biomarkers (e.g., MDA, SOD, GPx) to identify patients who may benefit from supplementation
Lyons CL, Roche HM